Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists

Japanese Journal of Pharmacology

Volumn 84, Issue 2, 2000, Pages 101-112

  Fisher, A ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Alzheimer's disease; Animal model; M1 muscarinic agonist; Tau; Amyloid

Indexed keywords

1 METHYLPIPERIDINE 4 SPIRO (2' METHYLTHIAZOLINE); ACETYLCHOLINE; AF 267B; AMYLOID BETA PROTEIN; BINB 99; CARBACHOL; CEVIMELINE; CHOLINE; DONEPEZIL; EPIBATIDINE; GALANTAMINE; LEVOFLOXACIN; METRIFONATE; MILAMELINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR ANTAGONIST; PHOSPHATIDYLCHOLINE; RIVASTIGMINE; SABCOMELINE; TACRINE; TAU PROTEIN; UNCLASSIFIED DRUG; XANOMELINE;

ALZHEIMER DISEASE; APOPTOSIS; CHOLINERGIC ACTIVITY; CHOLINERGIC STIMULATION; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; CORNEA OPACITY; FLATULENCE; GASTROINTESTINAL TOXICITY; HUMAN; METABOLIC REGULATION; NONHUMAN; PARKINSONISM; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; XEROSTOMIA;

EID: 0033758338     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.84.101     Document Type: Review

References (80)

1. Dementia: The neurochemical basis of putative transmitter orientated therapy
2. Pharmacological drug treatment of Alzheimer disease: The cholinergic system revisited
3. Clinical neurochemistry: Developments in dementia research based on brain bank material
4. Muscarinic agonists for the treatment of Alzheimer's disease: Progress and perspectives
5. Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists
6. Progress and perspectives in new muscarinic agonists
7. New perspectives on developing muscarinic agonists for treating Alzheimer's disease
8. Muscarinic receptor agonists in Alzheimer's disease. More than just symptomtic treatment
9. Potential role of muscarinic agonists in Alzheimer's disease
10. WAL 2014 FU (Talsaclidine): A preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease
11. Pharmacological studies on novel muscarinic agonists, 1-oxa-8-azaspiro[4.5]decane derivatives YM796 and YM954
12. Muscarinic agonists for the treatment of Alzheimer's disease: The case of combination therapy
13. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer Disease
14. Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease
15. Milameline (CI-979/RU35926): A muscarinic receptor agonist with cognition-activiting properties: Bichemical and in vivo characterization
16. SB202026: A novel muscarinic partial agonist with functional selectivity for M2 receptors
17. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4, and hM5 using microphysiometry
18. Pharmacological in vitro characterization of the arecoline bioisostere, Lu 25-109-T, a muscarinic compound with M1-agonistic and M2/M3-antagonistic properties
19. Discrete activation of transduction pathways associated with acetylcholine M1 receptor by several muscarinic ligands
20. Beta-amyloid and treatment opportunities for Alzheimer's disease
21. Muscarinic agonists in Alzheimer's Disease
22. Alzheimer's disease: Relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins
23. Modulation of beta-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors
24. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors
25. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta-A4 amyloid protein precursor
26. Amyloid precursor protein secretion via muscarinic receptors: Reduced desensitization using the M1-selective agonist AF102B
27. NGF promotes amyloid protein secretion via muscarinic receptor activation
28. Activation of protein kinase C inhibits cellular production of the amyloid beta-protein
29. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells
30. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from CHO M1 cells
31. Regulated secretion of β-amyloid precursor protein in rat brain
32. Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain
33. Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum
34. Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: A unifying hypothesis
35. Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to amyloid precursor protein secretion
36. M1 muscarinic agonists as potential disease modifying agents in Alzheimer's disease: Rationale and perspectives
37. In vivo regulation of amyloid precursor protein secretion in rat neocortex by cholinergic activity
38. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation
39. Cholinergic deafferentation of the rabbit cortex: A new animal model of A-beta deposition
40. Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester
41. 1 muscarinic agonists protect PC12M1 cells from growth factor deprivation and β-amyloid-induced apoptosis
42. A protein factor essential for microtubule assembly
43. Tau protein in normal and Alzheimer's disease brain: An update
44. Activation of m1-muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells
45. Muscarinic agonists reduce tau phosphorylation in transfected cells and in neurons
46. The influence of cholinergic mechanisms on neurodegeneration due to beta-amyloids and tau phosphorylation (translated from Portuguese)
47. Site-specific dephosphorylation of tau in apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment
48. The phosphorylation of tau: A critical stage in neurodevelopment and neurodegenerative processes
49. M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice
50. The effects of the acetylcholinesterase inhibitor ENA713 and the M1 agonist AF150(S) on apolipoprotein E deficient mice
51. Microcebus murinus, a convenient laboratory animal for the study of Alzheimer's disease
52. Beta-amyloid protein precursor in Microcebus murinus: Genotyping and brain localization
53. Quantitative analysis of tau protein-immunoreactive accumulations and beta-amyloid protein deposits in the cerebral cortex of the mouse lemur, Microcebus murinus
54. Cognitive and behavioral improvements in the aged primate Microcebus murinus following one year treatment with the M1 muscarinic agonist, AF150(S)
55. Cholinergic foundations of Alzheimer's disease therapy
56. Cholinergic receptors in human brain: Effects of aging and Alzheimer's disease
57. Is there a rationale for the use of acetyl-cholinesterase inhibitors in the therapy of Alzheimer's disease?
58. The effect of the selective reversible acetylcholiesterase inhibitor E2020 on extracellular acetylholine and biogenic amine levels in rat cortex
59. Effects of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats
60. Metrifonat and tacrine: A comparative study on their effect on acetylcholine dynamics in mouse brain
61. Essential role of neocortical acetylcholine in spatial memory
62. Muscarinic acetylcholine receptors activate expression of the Egr gene family of transcription factors
63. AF102B, a novel M1 agonist, enhanced learning in C57BL/10 mice with a long duration of action
64. 2 receptor antagonism: A viable strategy in the treatment of Alzheimer's disease
65. Cholinergic muscarinic receptor signaling by phosphoinositides signal transduction system in Alzheimer's disease
66. Lesion of septal-hippocampal neurons with 192 IgG-saporin alters function of M1 muscarinic receptors
67. Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons
68. Beta-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices
69. Nontoxic amyloid beta peptide 1-42 suppresses acetylcholine synthesis: Possible role in cholinergic dysfunction in Alzheimer's disease
70. Increased cerebrospinal fluid cAMP in Alzheimer's disease
71. Alzheimer's disease: Specific increases in a G-protein subunit (Gs-alpha) mRNA in hippocampal and cortical neurons
72. Intracellular cAMP inhibits constitutive and phorbol ester-stimulated secretory cleavage of amyloid precursor protein
73. Growth-factor like effects mediated by muscarinic receptors in PC12M1 cells
74. Muscarinic stimulation promotes cultured Purkinje cell survival: A role for acetylcholine in cerebellar development?
75. Novel muscarinic M1 receptor agonists promote survival of CNS neurons in primary cell culture
76. NGF-dependent neurotrophic-like effects of AF102B, an M1 muscarinic agonist, in PC12M1 cells
77. Regulation of APP processing by cholinergic neurotransmission
78. Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease
79. CSF biochemical markers for the early detection of Alzheimer's disease
80. Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation